reveromycin a has been researched along with Bone Loss, Osteoclastic in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
Authors | Studies |
---|---|
Asano, Y; Goto, S; Kako, S; Kawatani, M; Maeda, H; Miyazawa, K; Osada, H; Tabuchi, M | 1 |
Kawatani, M; Osada, H | 1 |
Goto, S; Kadota, M; Kawatani, M; Maeda, H; Miyazawa, K; Osada, H; Tabuchi, M; Tanaka, M; Yabumoto, T; Yamane, C; Yoshizako, M | 1 |
Kanoh, N; Kato, M; Kawatani, M; Lee, KH; Nagai, K; Nakagawa, H; Osada, H; Shinki, T; Stern, PH; Takami, M; Woo, JT; Yonezawa, T | 1 |
Cha, BY; Nagai, K; Teruya, T; Woo, JT; Yonezawa, T | 1 |
2 review(s) available for reveromycin a and Bone Loss, Osteoclastic
Article | Year |
---|---|
Osteoclast-targeting small molecules for the treatment of neoplastic bone metastases.
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Bone Neoplasms; Bone Resorption; Cell Differentiation; CSK Tyrosine-Protein Kinase; Diphosphonates; Ethers; Humans; Integrin alphaVbeta3; Osteoclasts; Protein-Tyrosine Kinases; Pyrans; Spiro Compounds; src-Family Kinases | 2009 |
Pharmacological topics of bone metabolism: antiresorptive microbial compounds that inhibit osteoclast differentiation, function, and survival.
Topics: Animals; Apoptosis; Bacteria; Bone Density Conservation Agents; Bone Resorption; Cell Differentiation; Cell Survival; Cyclosporine; Depsipeptides; Fungi; Heterocyclic Compounds, 3-Ring; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Osteoclasts; Prodigiosin; Pyrans; Spiro Compounds; Tacrolimus | 2008 |
3 other study(ies) available for reveromycin a and Bone Loss, Osteoclastic
Article | Year |
---|---|
Local administration of ReveromycinA ointment suppressed alveolar bone loss in mice.
Topics: Administration, Topical; Alveolar Bone Loss; Animals; Bone Resorption; Disease Models, Animal; Male; Mice, Inbred C57BL; Mice, Knockout; Ointments; Osteoclasts; Periodontal Diseases; Periodontitis; Pyrans; Spiro Compounds | 2021 |
Effect of Reveromycin A on experimental tooth movement in OPG-/- mice.
Topics: Acid Phosphatase; Alkaline Phosphatase; Alveolar Process; Animals; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Cell Count; Dental Alloys; Disease Models, Animal; Injections, Intraperitoneal; Isoenzymes; Male; Maxilla; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Knockout; Mutation; Nickel; Orthodontic Wires; Osteitis Deformans; Osteoclasts; Osteoporosis; Osteoprotegerin; Pyrans; Spiro Compounds; Tartrate-Resistant Acid Phosphatase; Titanium; Tooth Movement Techniques; X-Ray Microtomography | 2012 |
Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts.
Topics: Acids; Animals; Apoptosis; Bone and Bones; Bone Resorption; Culture Media; Female; Isoleucine-tRNA Ligase; Mice; Mice, Inbred Strains; Osteoclasts; Osteoporosis; Protein Biosynthesis; Pyrans; Rats; Rats, Sprague-Dawley; Spiro Compounds | 2006 |